Healthcare Realty Trust Analyst Ratings
Healthcare Realty Trust Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/10/2023 | 16.2% | Scotiabank | $19 → $17 | Maintains | Sector Perform |
| 10/06/2023 | 16.2% | BMO Capital | $20 → $17 | Maintains | Market Perform |
| 10/03/2023 | 16.2% | Wedbush | → $17 | Initiates Coverage On | → Outperform |
| 08/22/2023 | 16.2% | Citigroup | $19 → $17 | Maintains | Neutral |
| 08/11/2023 | 64.05% | Barclays | $25 → $24 | Maintains | Equal-Weight |
| 05/11/2023 | 70.88% | Barclays | $24 → $25 | Maintains | Overweight |
| 04/19/2023 | — | Wells Fargo | Initiates Coverage On | → Equal-Weight | |
| 03/29/2023 | 64.05% | Barclays | $28 → $24 | Maintains | Overweight |
| 03/06/2023 | 36.71% | Credit Suisse | $23 → $20 | Downgrades | Outperform → Neutral |
| 12/14/2022 | 36.71% | Citigroup | $22.5 → $20 | Downgrades | Buy → Neutral |
| 12/02/2022 | 50.38% | JP Morgan | $28 → $22 | Maintains | Neutral |
| 09/19/2022 | 91.39% | Citigroup | $27 → $28 | Upgrades | Neutral → Buy |
| 08/11/2022 | 105.06% | SMBC Nikko | → $30 | Upgrades | Neutral → Outperform |
| 07/18/2022 | 98.22% | Credit Suisse | $34 → $29 | Maintains | Outperform |
| 05/10/2022 | 118.73% | Berenberg | $35 → $32 | Downgrades | Buy → Hold |
| 04/26/2022 | 125.56% | Barclays | → $33 | Initiates Coverage On | → Overweight |
| 02/01/2022 | — | Credit Suisse | Initiates Coverage On | → Outperform | |
| 01/07/2022 | 132.4% | BMO Capital | → $34 | Downgrades | Outperform → Market Perform |
| 08/20/2021 | — | Raymond James | Downgrades | Strong Buy → Market Perform | |
| 07/29/2021 | 125.56% | Morgan Stanley | $31 → $33 | Maintains | Equal-Weight |
| 03/31/2021 | 111.89% | Wells Fargo | $29 → $31 | Maintains | Equal-Weight |
| 03/15/2021 | 111.89% | Morgan Stanley | $30 → $31 | Maintains | Equal-Weight |
| 01/28/2021 | 118.73% | Scotiabank | → $32 | Initiates Coverage On | → Sector Perform |
| 01/13/2021 | 125.56% | Jefferies | $30 → $33 | Upgrades | Hold → Buy |
| 09/18/2020 | 125.56% | Capital One | → $33 | Upgrades | Equal-Weight → Overweight |
| 09/02/2020 | 118.73% | Stifel | → $32 | Reinstates | → Buy |
| 08/31/2020 | 139.23% | Raymond James | $34 → $35 | Upgrades | Outperform → Strong Buy |
| 04/29/2020 | 132.4% | Raymond James | $38 → $34 | Maintains | Outperform |
| 04/07/2020 | 98.22% | Citigroup | $38 → $29 | Downgrades | Buy → Neutral |
| 04/03/2020 | 77.72% | Wells Fargo | $33 → $26 | Maintains | Equal-Weight |
| 04/03/2020 | 105.06% | JP Morgan | $35 → $30 | Maintains | Neutral |
| 03/26/2020 | 70.88% | Morgan Stanley | $33 → $25 | Maintains | Equal-Weight |
| 03/12/2020 | 159.74% | Raymond James | $36 → $38 | Maintains | Outperform |
| 03/09/2020 | 193.92% | BMO Capital | $35 → $43 | Upgrades | Market Perform → Outperform |
| 12/20/2019 | 132.4% | Mizuho | → $34 | Assumes | → Neutral |
| 12/12/2019 | — | Citigroup | Upgrades | Neutral → Buy | |
| 11/26/2019 | 139.23% | Stifel | $33 → $35 | Upgrades | Hold → Buy |
| 09/17/2019 | 125.56% | Morgan Stanley | $31 → $33 | Maintains | Equal-Weight |
| 06/20/2019 | 132.4% | Citigroup | → $34 | Initiates Coverage On | → Neutral |
| 01/08/2019 | — | Raymond James | Upgrades | Underperform → Market Perform | |
| 11/13/2018 | 118.73% | Mizuho | → $32 | Upgrades | Neutral → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月10日 | 16.2% | 加拿大豐業銀行 | $19→$17 | 維護 | 行業表現 |
| 10/06/2023 | 16.2% | 蒙特利爾銀行資本 | $20→$17 | 維護 | 市場表現 |
| 10/03/2023 | 16.2% | 韋德布什 | →$17 | 開始承保 | →跑贏大盤 |
| 2023年08月22日 | 16.2% | 花旗集團 | $19→$17 | 維護 | 中性 |
| 2023年08月11日 | 64.05% | 巴克萊 | $25→$24 | 維護 | 等重 |
| 2023年05月11日 | 70.88% | 巴克萊 | $24→$25 | 維護 | 超重 |
| 04/19/2023 | - | 富國銀行 | 開始承保 | →等重 | |
| 03/29/2023 | 64.05% | 巴克萊 | $28→$24 | 維護 | 超重 |
| 03/06/2023 | 36.71% | 瑞士信貸 | $23→$20 | 評級下調 | 跑贏→中性 |
| 2022年12月14日 | 36.71% | 花旗集團 | $22.5→$20 | 評級下調 | 購買→中性 |
| 12/02/2022 | 50.38% | 摩根大通 | $28→$22 | 維護 | 中性 |
| 2022/09/19 | 91.39% | 花旗集團 | $27→$28 | 升級 | 中性→購買 |
| 2022年08月11日 | 105.06% | SMBC日興 | →$30 | 升級 | 中性→表現優異 |
| 07/18/2022 | 98.22% | 瑞士信貸 | $34→$29 | 維護 | 跑贏大盤 |
| 2022年05月10日 | 118.73% | 貝倫伯格 | $35→$32 | 評級下調 | 購買→Hold |
| 04/26/2022 | 125.56% | 巴克萊 | →$33 | 開始承保 | →超重 |
| 02/01/2022 | - | 瑞士信貸 | 開始承保 | →跑贏大盤 | |
| 01/07/2022 | 132.4% | 蒙特利爾銀行資本 | →$34 | 評級下調 | 跑贏→市場表現 |
| 08/20/2021 | - | 雷蒙德·詹姆斯 | 評級下調 | 強勁的購買→市場表現 | |
| 07/29/2021 | 125.56% | 摩根士丹利 | $31→$33 | 維護 | 等重 |
| 03/31/2021 | 111.89% | 富國銀行 | $29→$31 | 維護 | 等重 |
| 03/15/2021 | 111.89% | 摩根士丹利 | $30→$31 | 維護 | 等重 |
| 2021年1月28日 | 118.73% | 加拿大豐業銀行 | →$32 | 開始承保 | →行業表現 |
| 2021/01/13 | 125.56% | 傑富瑞 | $30→$33 | 升級 | 持有→購買 |
| 09/18/2020 | 125.56% | 大寫一 | →$33 | 升級 | 等重→超重 |
| 09/02/2020 | 118.73% | Stifel | →$32 | 恢復 | →購買 |
| 08/31/2020 | 139.23% | 雷蒙德·詹姆斯 | $34→$35 | 升級 | 跑贏→強勢買入 |
| 04/29/2020 | 132.4% | 雷蒙德·詹姆斯 | $38→$34 | 維護 | 跑贏大盤 |
| 04/07/2020 | 98.22% | 花旗集團 | $38→$29 | 評級下調 | 購買→中性 |
| 04/03/2020 | 77.72% | 富國銀行 | $33→$26 | 維護 | 等重 |
| 04/03/2020 | 105.06% | 摩根大通 | $35→$30 | 維護 | 中性 |
| 03/26/2020 | 70.88% | 摩根士丹利 | $33→$25 | 維護 | 等重 |
| 03/12/2020 | 159.74% | 雷蒙德·詹姆斯 | $36→$38 | 維護 | 跑贏大盤 |
| 03/09/2020 | 193.92% | 蒙特利爾銀行資本 | $35→$43 | 升級 | 市場表現優於→ |
| 2019年12月20日 | 132.4% | 瑞穗 | →$34 | 假設 | →中性 |
| 2019年12月12日 | - | 花旗集團 | 升級 | 中性→購買 | |
| 2019年11月26日 | 139.23% | Stifel | $33→$35 | 升級 | 持有→購買 |
| 2019/09/17 | 125.56% | 摩根士丹利 | $31→$33 | 維護 | 等重 |
| 2019年06月20日 | 132.4% | 花旗集團 | →$34 | 開始承保 | →中性 |
| 2019年08月01日 | - | 雷蒙德·詹姆斯 | 升級 | 表現遜於→市場表現 | |
| 2018年11月13日 | 118.73% | 瑞穗 | →$32 | 升級 | 中性→購買 |
What is the target price for Healthcare Realty Trust (HR)?
醫療房地產信託基金(HR)的目標價格是多少？
The latest price target for Healthcare Realty Trust (NYSE: HR) was reported by Scotiabank on October 10, 2023. The analyst firm set a price target for $17.00 expecting HR to rise to within 12 months (a possible 16.20% upside). 11 analyst firms have reported ratings in the last year.
加拿大豐業銀行於2023年10月10日報道了Healthcare Realty Trust(紐約證券交易所代碼：HR)的最新目標價。這家分析公司將目標價定為17.00美元，預計人力資源將在12個月內升至(可能上漲16.20%)。過去一年，有11家分析公司公佈了評級。
What is the most recent analyst rating for Healthcare Realty Trust (HR)?
Healthcare Realty Trust(HR)的最新分析師評級是多少？
The latest analyst rating for Healthcare Realty Trust (NYSE: HR) was provided by Scotiabank, and Healthcare Realty Trust maintained their sector perform rating.
對Healthcare Realty Trust(紐約證券交易所代碼：HR)的最新分析師評級由加拿大豐業銀行提供，Healthcare Realty Trust維持其行業表現評級。
When is the next analyst rating going to be posted or updated for Healthcare Realty Trust (HR)?
Healthcare Realty Trust(HR)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Healthcare Realty Trust, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Healthcare Realty Trust was filed on October 10, 2023 so you should expect the next rating to be made available sometime around October 10, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Healthcare Realty Trust的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。醫療房地產信託基金的上一次評級是在2023年10月10日提交的，因此你應該預計下一次評級將在2024年10月10日左右的某個時候公佈。
Is the Analyst Rating Healthcare Realty Trust (HR) correct?
分析師對Healthcare Realty Trust(HR)的評級正確嗎？
While ratings are subjective and will change, the latest Healthcare Realty Trust (HR) rating was a maintained with a price target of $19.00 to $17.00. The current price Healthcare Realty Trust (HR) is trading at is $14.63, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的醫療房地產信託(HR)評級維持不變，目標價在19.00美元至17.00美元之間。Healthcare Realty Trust(HR)目前的交易價格為14.63美元，超出了分析師的預測範圍。
譯文內容由第三人軟體翻譯。